<!DOCTYPE html>
<html lang="en-us"
  dir="ltr">

<head>
  <meta charset="utf-8">
<meta name="viewport" content="width=device-width">



<link rel="icon" type="image/ico" href="https://reports.muthu.co/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://reports.muthu.co/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://reports.muthu.co/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="192x192" href="https://reports.muthu.co/android-chrome-192x192.png">
<link rel="apple-touch-icon" sizes="180x180" href="https://reports.muthu.co/apple-touch-icon.png">

<meta name="description" content=""/>



<title>
    
    Healthcare Global Enterprises Ltd - Mar 2025 Earnings Call Transcript Analysis | Financial Report Insights
    
</title>
<link href="/_pagefind/pagefind-ui.css" rel="stylesheet">
<script src="/_pagefind/pagefind-ui.js"></script>
<link rel="canonical" href="https://reports.muthu.co/posts/healthcare-global-enterprises-ltd---mar-2025-earnings-call-transcript-analysis/"/>

<meta property="og:url" content="https://reports.muthu.co/posts/healthcare-global-enterprises-ltd---mar-2025-earnings-call-transcript-analysis/">
  <meta property="og:site_name" content="Financial Report Insights">
  <meta property="og:title" content="Healthcare Global Enterprises Ltd - Mar 2025 Earnings Call Transcript Analysis">
  <meta property="og:description" content="Earnings Call Transcript Analysis Report # HCG Q3 FY&#39;25 Earnings Call Analysis # Financial Performance # Key Financial Metrics: Revenue: Q3 FY ‘25: INR 559 crores (highest ever quarterly revenue), 19% YoY growth. 9 Months FY&#39;25: INR 1,638 crores, 16% YoY growth. Adjusted EBITDA: Q3 FY ‘25: INR 92.3 crores, 15% YoY growth. Adjusted EBITDA Margin: Q3 FY ‘25: 16.5%. PAT Growth: 23% YoY. MG Hospital (Vizag) Revenue: INR 25 crores, with a 24% margin. ARPOB (Average Revenue Per Occupied Bed): Grew by 3.5%, standing at INR 44,284. Established centers: INR 42,798 (2.8% growth). Emerging centers: INR 66,000 (12.3% growth). Effective Tax Rate: 3% for a 9-month period. South Mumbai Center Losses: INR 10-12 Crores for FY&#39;25 Comparison with Previous Periods: Q3 revenue showed a 19% YoY increase. 9-month revenue showed a 16% YoY increase. Adjusted EBITDA grew by 15% YoY in Q3. Bed occupancy improved from 52% in Q3 FY24 to 55% in Q3 FY25 Revised Guidance/Forecasts: Expect stronger growth in Q4 FY ‘25 (revenue and EBITDA). Expect EBITDA margin to expand by 1% to 1.5% in the next financial year compared to FY25. South Mumbai center expected to break even by Q1 of next financial year. Capex for the year estimated to be INR 275 crores, with INR 172 crores already deployed. Maintenance Capex to be around 100cr per annum. Areas of Growth/Decline: Growth: Oncology business (post MG Hospital Vizag acquisition): 24% growth. Emerging centers: 25% YoY revenue growth. Kolkata centers: 40% growth. South Mumbai center: 28% growth. Chemotherapy sessions: 19% growth. Established centers: 20% revenue growth, 14% EBITDA growth. Core HCG Centers (excluding Milann): 21% revenue increase. 16% EBITDA growth, with a 20% EBITDA margin Oncology Centers (excluding Milann, multispeciality, and MG Vizag): 18% revenue increase, 14% EBITDA growth, 21% margin. Decline: Milann revenue continues to decline, although management is optimistic about a turnaround. Strategic Initiatives &amp; Business Updates # Major Strategic Announcements: Ownership Change: CVC sold a majority stake to KKR. KKR is expected to hold 54-77% equity stake post-transaction and open offer. Dr. B.S. Ajaikumar will be a co-promoter. CVC will be a public shareholder Focus on Precision Oncology: Emphasis on personalized treatment, genomics, proteomics, research, and academics. Restructuring of diagnostic business, Triesta. New Products/Services/Markets: Continued focus on expanding the hub-and-spoke model with infusion clinics. Operational Changes: Dr. B.S. Ajaikumar will transition from Executive Chairman to Chairman of the Board, focusing on clinical excellence, research, and academics, with limited involvement in daily operations. Consolidation of MG Hospital operations in Vizag. Strengthening the andrology department at Milann. Ongoing/Completed Projects: Two new brownfield centers in Bangalore are expected to be operationalized in FY ‘26. Market &amp; Competitive Landscape # Industry Trends: Oncology is growing rapidly in India. Indian genomics is different from Caucasians, necessitating localized treatment approaches. Infertility is becoming a major issue in India. Medical Tourism impacted due to the Indian government restricting medical visas. Competitive Positioning: HCG positions itself as a leader in comprehensive cancer care. Focus on asset-light model for efficient expansion. Market Challenges/Opportunities: Opportunity: Growing demand for oncology services in India. Opportunity: Potential for mergers and acquisitions. Challenge: Geopolitical issues impacting international business, specifically mentioned for the South Mumbai center. Market Share/Positioning: Indicates growth in market share across regions. Risk Factors &amp; Challenges # Concerns/Challenges: Seasonality impacting Q3 performance. Geopolitical issues impacting international patient flow, particularly from Bangladesh. Decline in Milann revenue due to increased competition. Operational losses from new centers. Regulatory Issues: Mention of regulatory processes related to the KKR acquisition and open offer. Operational Constraints: Mention of subdued international business Market Uncertainties: Uncertainty regarding the open offer participation. Forward-Looking Statements # Outlook and Projections: Expect continued strong growth in emerging centers. Expect recovery in international business by the upcoming quarter. Anticipates normalization of modality mix and revenue scale-up, improving margins. Commitments/Targets: Focus on long-term growth with KKR. Aim to minimize cancer recurrence. South Mumbai center expected to break even by Q1 of next financial year. Planned Investments: Continued investment in medical infrastructure, specialized treatments, and clinical talent. Capital expenditure of approximately INR275-280 crores for FY25 and FY26. Sentiment: Positive sentiment about future performance, and “gung-ho about the potential of the organization”. Q&amp;A Insights # Most Pressing Analyst Questions: Clarification on the shareholding structure post-acquisition. Dr. Ajaikumar’s role in the organization after the transition. Margin trajectory and impact of new centers. Growth rate of established centers. Performance and turnaround plans for Mumbai centers (Borivali and South Mumbai). Impact of the KKR acquisition on business plans. Outlook on international patient business. Capex guidance and debt levels. Strategy for Milann. Challenging Questions &amp; Responses: Debt Levels: Management stated they are comfortable with current debt levels and banking covenants. Milann’s Performance: Management acknowledged the decline but expressed optimism about a turnaround due to new strategies and leadership changes. Y-o-Y Margin Pressure in Established Centers: Management attributed this to lower operating leverage due to revenue reduction and a higher proportion of pharmacy business, expecting normalization in Q4. Indirect Answers: Specific details on the timeline of the open offer were deferred, citing regulatory processes. Details about profit/loss contribution on the PBT level for MG Hospital was not disclosed. New Information: Confirmation that Dr. Ajaikumar will be a co-promoter with KKR. CVC will be classified as a public shareholder. South Mumbai center’s EBITDA loss for FY ‘25 is estimated at INR 10-12 crores. Andrology focus as a growth driver for Milann. Management Tone &amp; Sentiment # Overall Tone: The overall tone is very confident and optimistic. Management repeatedly emphasizes the company’s strong performance, growth potential, and strategic direction. Changes in Language: No significant changes were noted compared to hypothetical previous calls, as this is the first analysis. However, the language is strongly positive, emphasizing achievements and future plans. Confidence/Concern: Confident: Growth prospects, clinical excellence, operational efficiency, new partnerships, and market leadership. Concerned (but optimistic): Milann’s performance, although management is actively addressing the challenges. Impact of geopolitical issues on international business, but expect a quick recovery. Key Takeaways # Strong Financial Performance: HCG reported its highest-ever quarterly revenue and solid YoY growth, demonstrating resilience despite seasonality. Strategic Shift: The KKR acquisition marks a significant strategic shift, with Dr. Ajaikumar focusing on clinical excellence and research, while KKR takes a majority stake. Growth Focus: HCG is committed to both organic growth (existing centers, brownfield expansions) and potential inorganic growth (mergers and acquisitions). Turnaround Potential: While Milann faces challenges, management is optimistic about a turnaround. The South Mumbai center is also projected to break even soon. Positive Outlook: Management is highly confident about the future, expecting continued growth, margin expansion, and a strong performance in the coming quarters. International business is expected to rebound. Effective tax rate is low (3%) due to the recognision of a deferred tax. Download Transcript">
  <meta property="og:locale" content="en_us">
  <meta property="og:type" content="article">
    <meta property="article:section" content="posts">
    <meta property="article:published_time" content="2025-03-06T11:57:54+00:00">
    <meta property="article:modified_time" content="2025-03-06T11:57:54+00:00">
    <meta property="article:tag" content="Healthcare Global Enterprises Ltd.">
    <meta property="article:tag" content="HCG">
    <meta property="article:tag" content="Hospitals & Clinics">
    <meta property="article:tag" content="Healthcare">
    <meta property="article:tag" content="Small Cap">
    <meta property="article:tag" content="Earnings Call">













<link rel="stylesheet" href="/assets/combined.min.83aead7461ea8e7fcfbb79b8c9400e1ec33efe08796484ba7a94d30f7b4923a8.css" media="all">




      <script async src="https://www.googletagmanager.com/gtag/js?id=G-T7PH4WNH24"></script>
      <script>
        var doNotTrack = false;
        if ( false ) {
          var dnt = (navigator.doNotTrack || window.doNotTrack || navigator.msDoNotTrack);
          var doNotTrack = (dnt == "1" || dnt == "yes");
        }
        if (!doNotTrack) {
          window.dataLayer = window.dataLayer || [];
          function gtag(){dataLayer.push(arguments);}
          gtag('js', new Date());
          gtag('config', 'G-T7PH4WNH24');
        }
      </script>




<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js?client=ca-pub-3609399560636561" crossorigin="anonymous"></script>
</head>







<body class="light">
  <div class="content">
    <header>
      

<div class="header">

    
    <div id="search"></div>
</div>

    </header>
    <main class="main">
      





<div class="breadcrumbs">
    
    <a href="/">Home</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a href="/posts/">Posts</a>
    <span class="breadcrumbs-separator"> > </span>
    
    <a class="breadcrumbs-current" href="/posts/healthcare-global-enterprises-ltd---mar-2025-earnings-call-transcript-analysis/">Healthcare Global Enterprises Ltd - Mar 2025 Earnings Call Transcript Analysis</a>
</div>



<div >

  <div class="single-intro-container">

    

    <h1 class="single-title" data-pagefind-body>Healthcare Global Enterprises Ltd - Mar 2025 Earnings Call Transcript Analysis</h1>
    

    

    <p class="single-readtime">
      
      
      
      <time datetime="2025-03-06T11:57:54&#43;00:00">March 6, 2025</time>
      

      
      &nbsp; · &nbsp;
      6 min read
      
    </p>

  </div>

  

  
  

  <div class="single-tags">
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare-global-enterprises-ltd./">#Healthcare Global Enterprises Ltd.</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/hcg/">#HCG</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/hospitals--clinics/">#Hospitals &amp; Clinics</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/healthcare/">#Healthcare</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/small-cap/">#Small Cap</a>
    </span>
    
    
    <span>
      <a href="https://reports.muthu.co/tags/earnings-call/">#Earnings Call</a>
    </span>
    
    
  </div>

  
  

  

  
  <aside class="toc">
    <p><strong>Table of contents</strong></p>
    <nav id="TableOfContents">
  <ul>
    <li><a href="#earnings-call-transcript-analysis-report">Earnings Call Transcript Analysis Report</a></li>
    <li><a href="#hcg-q3-fy25-earnings-call-analysis">HCG Q3 FY'25 Earnings Call Analysis</a>
      <ul>
        <li><a href="#financial-performance">Financial Performance</a></li>
        <li><a href="#strategic-initiatives--business-updates">Strategic Initiatives &amp; Business Updates</a></li>
        <li><a href="#market--competitive-landscape">Market &amp; Competitive Landscape</a></li>
        <li><a href="#risk-factors--challenges">Risk Factors &amp; Challenges</a></li>
        <li><a href="#forward-looking-statements">Forward-Looking Statements</a></li>
        <li><a href="#qa-insights">Q&amp;A Insights</a></li>
        <li><a href="#management-tone--sentiment">Management Tone &amp; Sentiment</a></li>
        <li><a href="#key-takeaways">Key Takeaways</a></li>
      </ul>
    </li>
  </ul>
</nav>
  </aside>
  

  

  <div class="single-content">
    <h2 class="heading" id="earnings-call-transcript-analysis-report">
  Earnings Call Transcript Analysis Report
  <a class="anchor" href="#earnings-call-transcript-analysis-report">#</a>
</h2>
<h2 class="heading" id="hcg-q3-fy25-earnings-call-analysis">
  HCG Q3 FY'25 Earnings Call Analysis
  <a class="anchor" href="#hcg-q3-fy25-earnings-call-analysis">#</a>
</h2>
<h3 class="heading" id="financial-performance">
  Financial Performance
  <a class="anchor" href="#financial-performance">#</a>
</h3>
<ul>
<li><strong>Key Financial Metrics:</strong>
<ul>
<li><strong>Revenue:</strong> Q3 FY &lsquo;25: INR 559 crores (highest ever quarterly revenue), 19% YoY growth. 9 Months FY'25: INR 1,638 crores, 16% YoY growth.</li>
<li><strong>Adjusted EBITDA:</strong> Q3 FY &lsquo;25: INR 92.3 crores, 15% YoY growth.</li>
<li><strong>Adjusted EBITDA Margin:</strong> Q3 FY &lsquo;25: 16.5%.</li>
<li><strong>PAT Growth:</strong> 23% YoY.</li>
<li><strong>MG Hospital (Vizag) Revenue:</strong> INR 25 crores, with a 24% margin.</li>
<li><strong>ARPOB (Average Revenue Per Occupied Bed):</strong> Grew by 3.5%, standing at INR 44,284. Established centers: INR 42,798 (2.8% growth). Emerging centers: INR 66,000 (12.3% growth).</li>
<li><strong>Effective Tax Rate:</strong> 3% for a 9-month period.</li>
<li><strong>South Mumbai Center Losses:</strong> INR 10-12 Crores for FY'25</li>
</ul>
</li>
<li><strong>Comparison with Previous Periods:</strong>
<ul>
<li>Q3 revenue showed a 19% YoY increase.</li>
<li>9-month revenue showed a 16% YoY increase.</li>
<li>Adjusted EBITDA grew by 15% YoY in Q3.</li>
<li>Bed occupancy improved from 52% in Q3 FY24 to 55% in Q3 FY25</li>
</ul>
</li>
<li><strong>Revised Guidance/Forecasts:</strong>
<ul>
<li>Expect stronger growth in Q4 FY &lsquo;25 (revenue and EBITDA).</li>
<li>Expect EBITDA margin to expand by 1% to 1.5% in the next financial year compared to FY25.</li>
<li>South Mumbai center expected to break even by Q1 of next financial year.</li>
<li>Capex for the year estimated to be INR 275 crores, with INR 172 crores already deployed.</li>
<li>Maintenance Capex to be around 100cr per annum.</li>
</ul>
</li>
<li><strong>Areas of Growth/Decline:</strong>
<ul>
<li><strong>Growth:</strong>
<ul>
<li>Oncology business (post MG Hospital Vizag acquisition): 24% growth.</li>
<li>Emerging centers: 25% YoY revenue growth.</li>
<li>Kolkata centers: 40% growth.</li>
<li>South Mumbai center: 28% growth.</li>
<li>Chemotherapy sessions: 19% growth.</li>
</ul>
</li>
<li>Established centers: 20% revenue growth, 14% EBITDA growth.</li>
<li>Core HCG Centers (excluding Milann): 21% revenue increase. 16% EBITDA growth, with a 20% EBITDA margin</li>
<li>Oncology Centers (excluding Milann, multispeciality, and MG Vizag): 18% revenue increase, 14% EBITDA growth, 21% margin.</li>
<li><strong>Decline:</strong>
<ul>
<li>Milann revenue continues to decline, although management is optimistic about a turnaround.</li>
</ul>
</li>
</ul>
</li>
</ul>
<h3 class="heading" id="strategic-initiatives--business-updates">
  Strategic Initiatives &amp; Business Updates
  <a class="anchor" href="#strategic-initiatives--business-updates">#</a>
</h3>
<ul>
<li><strong>Major Strategic Announcements:</strong>
<ul>
<li><strong>Ownership Change:</strong> CVC sold a majority stake to KKR. KKR is expected to hold 54-77% equity stake post-transaction and open offer. Dr. B.S. Ajaikumar will be a co-promoter. CVC will be a public shareholder</li>
<li><strong>Focus on Precision Oncology:</strong> Emphasis on personalized treatment, genomics, proteomics, research, and academics.</li>
<li>Restructuring of diagnostic business, Triesta.</li>
</ul>
</li>
<li><strong>New Products/Services/Markets:</strong>
<ul>
<li>Continued focus on expanding the hub-and-spoke model with infusion clinics.</li>
</ul>
</li>
<li><strong>Operational Changes:</strong>
<ul>
<li>Dr. B.S. Ajaikumar will transition from Executive Chairman to Chairman of the Board, focusing on clinical excellence, research, and academics, with limited involvement in daily operations.</li>
<li>Consolidation of MG Hospital operations in Vizag.</li>
<li>Strengthening the andrology department at Milann.</li>
</ul>
</li>
<li><strong>Ongoing/Completed Projects:</strong>
<ul>
<li>Two new brownfield centers in Bangalore are expected to be operationalized in FY &lsquo;26.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="market--competitive-landscape">
  Market &amp; Competitive Landscape
  <a class="anchor" href="#market--competitive-landscape">#</a>
</h3>
<ul>
<li><strong>Industry Trends:</strong>
<ul>
<li>Oncology is growing rapidly in India.</li>
<li>Indian genomics is different from Caucasians, necessitating localized treatment approaches.</li>
<li>Infertility is becoming a major issue in India.</li>
<li>Medical Tourism impacted due to the Indian government restricting medical visas.</li>
</ul>
</li>
<li><strong>Competitive Positioning:</strong>
<ul>
<li>HCG positions itself as a leader in comprehensive cancer care.</li>
<li>Focus on asset-light model for efficient expansion.</li>
</ul>
</li>
<li><strong>Market Challenges/Opportunities:</strong>
<ul>
<li><strong>Opportunity:</strong> Growing demand for oncology services in India.</li>
<li><strong>Opportunity:</strong> Potential for mergers and acquisitions.</li>
<li><strong>Challenge:</strong> Geopolitical issues impacting international business, specifically mentioned for the South Mumbai center.</li>
</ul>
</li>
<li><strong>Market Share/Positioning:</strong>
<ul>
<li>Indicates growth in market share across regions.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="risk-factors--challenges">
  Risk Factors &amp; Challenges
  <a class="anchor" href="#risk-factors--challenges">#</a>
</h3>
<ul>
<li><strong>Concerns/Challenges:</strong>
<ul>
<li>Seasonality impacting Q3 performance.</li>
<li>Geopolitical issues impacting international patient flow, particularly from Bangladesh.</li>
<li>Decline in Milann revenue due to increased competition.</li>
<li>Operational losses from new centers.</li>
</ul>
</li>
<li><strong>Regulatory Issues:</strong>
<ul>
<li>Mention of regulatory processes related to the KKR acquisition and open offer.</li>
</ul>
</li>
<li><strong>Operational Constraints:</strong>
<ul>
<li>Mention of subdued international business</li>
</ul>
</li>
<li><strong>Market Uncertainties:</strong>
<ul>
<li>Uncertainty regarding the open offer participation.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="forward-looking-statements">
  Forward-Looking Statements
  <a class="anchor" href="#forward-looking-statements">#</a>
</h3>
<ul>
<li><strong>Outlook and Projections:</strong>
<ul>
<li>Expect continued strong growth in emerging centers.</li>
<li>Expect recovery in international business by the upcoming quarter.</li>
<li>Anticipates normalization of modality mix and revenue scale-up, improving margins.</li>
</ul>
</li>
<li><strong>Commitments/Targets:</strong>
<ul>
<li>Focus on long-term growth with KKR.</li>
<li>Aim to minimize cancer recurrence.</li>
<li>South Mumbai center expected to break even by Q1 of next financial year.</li>
</ul>
</li>
<li><strong>Planned Investments:</strong>
<ul>
<li>Continued investment in medical infrastructure, specialized treatments, and clinical talent.</li>
<li>Capital expenditure of approximately INR275-280 crores for FY25 and FY26.</li>
</ul>
</li>
<li><strong>Sentiment:</strong>
<ul>
<li>Positive sentiment about future performance, and &ldquo;gung-ho about the potential of the organization&rdquo;.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="qa-insights">
  Q&amp;A Insights
  <a class="anchor" href="#qa-insights">#</a>
</h3>
<ul>
<li><strong>Most Pressing Analyst Questions:</strong>
<ul>
<li>Clarification on the shareholding structure post-acquisition.</li>
<li>Dr. Ajaikumar&rsquo;s role in the organization after the transition.</li>
<li>Margin trajectory and impact of new centers.</li>
<li>Growth rate of established centers.</li>
<li>Performance and turnaround plans for Mumbai centers (Borivali and South Mumbai).</li>
<li>Impact of the KKR acquisition on business plans.</li>
<li>Outlook on international patient business.</li>
<li>Capex guidance and debt levels.</li>
<li>Strategy for Milann.</li>
</ul>
</li>
<li><strong>Challenging Questions &amp; Responses:</strong>
<ul>
<li><strong>Debt Levels:</strong> Management stated they are comfortable with current debt levels and banking covenants.</li>
<li><strong>Milann&rsquo;s Performance:</strong> Management acknowledged the decline but expressed optimism about a turnaround due to new strategies and leadership changes.</li>
<li><strong>Y-o-Y Margin Pressure in Established Centers:</strong> Management attributed this to lower operating leverage due to revenue reduction and a higher proportion of pharmacy business, expecting normalization in Q4.</li>
</ul>
</li>
<li><strong>Indirect Answers:</strong>
<ul>
<li>Specific details on the timeline of the open offer were deferred, citing regulatory processes.</li>
<li>Details about profit/loss contribution on the PBT level for MG Hospital was not disclosed.</li>
</ul>
</li>
<li><strong>New Information:</strong>
<ul>
<li>Confirmation that Dr. Ajaikumar will be a co-promoter with KKR.</li>
<li>CVC will be classified as a public shareholder.</li>
<li>South Mumbai center&rsquo;s EBITDA loss for FY &lsquo;25 is estimated at INR 10-12 crores.</li>
<li>Andrology focus as a growth driver for Milann.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="management-tone--sentiment">
  Management Tone &amp; Sentiment
  <a class="anchor" href="#management-tone--sentiment">#</a>
</h3>
<ul>
<li><strong>Overall Tone:</strong> The overall tone is very confident and optimistic. Management repeatedly emphasizes the company&rsquo;s strong performance, growth potential, and strategic direction.</li>
<li><strong>Changes in Language:</strong> No significant changes were noted compared to hypothetical previous calls, as this is the first analysis. However, the language is strongly positive, emphasizing achievements and future plans.</li>
<li><strong>Confidence/Concern:</strong>
<ul>
<li><strong>Confident:</strong> Growth prospects, clinical excellence, operational efficiency, new partnerships, and market leadership.</li>
<li><strong>Concerned (but optimistic):</strong> Milann&rsquo;s performance, although management is actively addressing the challenges. Impact of geopolitical issues on international business, but expect a quick recovery.</li>
</ul>
</li>
</ul>
<h3 class="heading" id="key-takeaways">
  Key Takeaways
  <a class="anchor" href="#key-takeaways">#</a>
</h3>
<ol>
<li><strong>Strong Financial Performance:</strong> HCG reported its highest-ever quarterly revenue and solid YoY growth, demonstrating resilience despite seasonality.</li>
<li><strong>Strategic Shift:</strong> The KKR acquisition marks a significant strategic shift, with Dr. Ajaikumar focusing on clinical excellence and research, while KKR takes a majority stake.</li>
<li><strong>Growth Focus:</strong> HCG is committed to both organic growth (existing centers, brownfield expansions) and potential inorganic growth (mergers and acquisitions).</li>
<li><strong>Turnaround Potential:</strong> While Milann faces challenges, management is optimistic about a turnaround. The South Mumbai center is also projected to break even soon.</li>
<li><strong>Positive Outlook:</strong> Management is highly confident about the future, expecting continued growth, margin expansion, and a strong performance in the coming quarters.</li>
<li>International business is expected to rebound.</li>
<li>Effective tax rate is low (3%) due to the recognision of a deferred tax.</li>
</ol>



<div class="button-container">    
    <a href="https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8b81c48-e01f-48a4-98c4-b270b8711902.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    



    
  </div>

  


  

  
  

<div class="single-pagination">
    <hr />

    <div class="flex">

        <div class="single-pagination-prev">
            
            <div class="single-pagination-container-prev">
                <div class="single-pagination-text">←</div>
                <div class="single-pagination-text">
                    <a href="/posts/ksb-ltd---mar-2025-earnings-call-transcript-analysis/">
                        KSB Ltd - Mar 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
            </div>
            
        </div>

        <div class="single-pagination-next">
            
            <div class="single-pagination-container-next">
                <div class="single-pagination-text">
                    <a href="/posts/schaeffler-india-ltd---mar-2025-earnings-call-transcript-analysis/">
                        Schaeffler India Ltd - Mar 2025 Earnings Call Transcript Analysis
                    </a>
                </div>
                <div class="single-pagination-text">→</div>
            </div>
            
        </div>

    </div>

    <hr />
</div>



  <div id="disqus_thread"></div>
<script>
    

    

    (function() { 
    var d = document, s = d.createElement('script');
    s.src = 'https://muthuai.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
    })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
  

  

  
  <div class="back-to-top">
    <a href="#top">
      back to top
    </a>
  </div>
  

</div>


    </main>
  </div>

  <footer>
    

    
    
    
    <p>Made with ♥ in India</p>
    


  </footer>

  

</body>

<script>

  function isAuto() {
    return document.body.classList.contains("auto");
  }

  function setTheme() {
    if (!isAuto()) {
      return
    }

    document.body.classList.remove("auto");
    let cls = "light";
    if (window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches) {
      cls = "dark";
    }

    document.body.classList.add(cls);
  }

  function invertBody() {
    document.body.classList.toggle("dark");
    document.body.classList.toggle("light");
  }

  if (isAuto()) {
    window.matchMedia('(prefers-color-scheme: dark)').addListener(invertBody);
  }

  setTheme();

</script>
<script>
    window.addEventListener('DOMContentLoaded', (event) => {
        new PagefindUI({ element: "#search", showSubResults: false, showImages: false });
    });
</script>
<script defer src="/js/copy-code.js"></script>
</html>